Fulltext
The full text of this article is available on the PDF file.
Zahedan Journal of Research in Medical Sciences
The Official Journal of Zahedan University of Medical Sciences
e-ISSN 2383-2894
Image Credit:Zahedan J Res Med Sci
Outline
Efficacy of interferon β1a (Cinnovex) in relapsing-remitting multiple sclerosis patients
Authors
1Assistant Professor of Neurology, Jundishapur University of Medical Sciences and Health Services, Ahwaz, Iran.
2Assistant Professor of Neurology, Jundishapur University of Medical Sciences and Health Services, Ahwaz, Iran
3General Physician, Clinical Research Center, Jundishapur University of Medical Sciences and Health Services, Ahwaz, Iran.
*Corresponding Author: Assistant Professor of Neurology, Jundishapur University of Medical Sciences and Health Services, Ahwaz, Iran. Email: sharafaddinzadeh@yahoo.com
Published online:Sep 29, 2010
Article type:Research Article
Received:Jan 20, 2010
Accepted:Jul 27, 2010
How to Cite:Sharafaddinzadeh N, Majdinasab N, Ghiasian M, Moravej-Aleali A. Efficacy of interferon β1a (Cinnovex) in relapsing-remitting multiple sclerosis patients. Zahedan J Res Med Sci. 2011;13(2):e94056. doi:
Abstract
Background : Multiple sclerosis is an inflammatory, chronic disease of the centre nervous system with demyelination in brain and spinal cord. Disability is evaluated by EDSS (Expanded Disability Scale Score). IFN β1a uses to prevent relapse rate and EDSS progression. The aim of this study was to evaluate efficacy of IFN β1a (Cinnovex) in relapsing- remitting multiple sclerosis patients.
Materials and Method: In this clinical trial, we evaluated 121 patients with RRMS registered in Khouzestan MS society during Nov. 2007 until Nov. 2008. Forty one patients went under treatment with Cinnovex. Forty patients in control group 1 received Avonex and 40 patients in control group 2 had no medication. After one year, results compared in all groups for EDSS or relapse rate.
Results: At the end of study, there was no significant changes in the base line EDSS (1.95±1.08) and EDSS after one year (1.97±1.36) (p>0.05), but significant decrease in relapse rate after one year treatment with Cinnovex (p<0.01). EDSS showed no significant increase in Avonex group (p>0.05), but significant increase in control group (p<0.001). Yearly relapse rate decreased in both group, but with significant changes in Avonex group (p<0.005). In our study, Cinnovex has similar effect like Avonex to reduce EDSS progression and relapse rate in patients with relapsing-remitting multiple sclerosis (p<0.05).
Conclusion: Cinnovex is an effective drug in the reduction of relapse rate and EDSS progress in relapsing-remitting multiple sclerosis patients
Highlights
References
- 1.The References of this article are available on the PDF file.
Copyright
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
27
Jun
2015
Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis
Nastaran Madjdinasab,
Seyed Ehsan Mohammadiany Nejad,
Shahram Tarahomi,
Fatemeh Sadr,
Mohammad Bahadoram
Madjdinasab N, Mohammadiany Nejad SE, Tarahomi S, Sadr F, Bahadoram M. Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis. Jentashapir J Cell Mol Biol. 2015;6(3):e29201. doi: https://doi.org/10.5812/jjhr.6(3)2015.29201
12
Sep
2010
Combination therapy of Avonex and doxycycline in patients with multiple sclerosis
Naser Sharafaddinzadeh,
Nastaran Majdinasab,
Majid Keyhanifard,
Armaghan Moravej-Aleali
Sharafaddinzadeh N, Majdinasab N, Keyhanifard M, Moravej-Aleali A. Combination therapy of Avonex and doxycycline in patients with multiple sclerosis. Zahedan J Res Med Sci. 2011;12(5):e94106. doi:
31
Jul
2019
A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Βeta-interferon I-a Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran
Seyed Massood Nabavi,
Roya Abolfazli,
Ali Etemadrezaei,
Hamed Hosseini,
Nahid Moradi,
Sanaz Shahriari
,et al.Nabavi SM, Abolfazli R, Etemadrezaei A, Hosseini H, Moradi N, et al. A Comparison Study of Efficacy and Safety of a Biosimilar Form of Intramuscular Βeta-interferon I-a Versus the Reference Product: A Randomized Controlled Clinical Trial in Iran. Iran J Pharm Res. 2019;18(3):e126180. doi: https://doi.org/10.22037/ijpr.2019.14503.12441
1
Nov
2015
Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial
Akbar Hamzei Moghaddam,
Rostam Seiffaddini,
Asma Najafzadeh,
Hossien Ali Ghaffaripour,
Peyman Arasteh,
Zeinab Movahhedi
,et al.Hamzei Moghaddam A, Seiffaddini R, Najafzadeh A, Ghaffaripour HA, Arasteh P, et al. Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial. Zahedan J Res Med Sci. 2015;17(11):e2227. doi: https://doi.org/10.17795/zjrms-2227
20
Oct
2019
Rheumatoid Arthritis in a Patient with Multiple Sclerosis Who Received INF β1-α: A Case Report
Abdorreza Naser Moghadasi
Naser Moghadasi A. Rheumatoid Arthritis in a Patient with Multiple Sclerosis Who Received INF β1-α: A Case Report. J Kermanshah Univ Med Sci. 2019;23(4):e92751. doi: https://doi.org/10.5812/jkums.92751
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 0
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 6 hours ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0